Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

Launched by SUN YAT-SEN UNIVERSITY · Oct 28, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at the use of two treatments, Tislelizumab alone or combined with Lenvatinib, for patients who have recurrent hepatocellular carcinoma (a type of liver cancer) and can still undergo surgery. The goal is to see how effective and safe these treatments are before surgery, which is called neoadjuvant treatment. The trial is currently recruiting participants aged 65 to 74, but they also welcome younger patients. To qualify, participants must have been diagnosed with this type of liver cancer after previous treatment, have at least one measurable tumor, and agree to provide some samples for testing.

If you or someone you know is considering joining this trial, participants will undergo regular assessments to monitor their health and the effectiveness of the treatments. However, there are some important factors to consider: individuals who have received certain previous treatments, have cancer spread beyond the liver, or have specific health conditions may not be eligible. This trial provides an opportunity to explore new treatment options that could improve outcomes for patients facing recurrent liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed as recurrent hepatocellular carcinoma after curative treatment;
• • 2. The criteria for resectability is met;
• • 3. Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment;
• • 4. Eastern Cooperative Oncology Group score 0-1, Child-pugh score 5-7;
• • 5. Agree to biopsy and blood sample collection;
• • 6. Adequate organ and marrow function.
• Exclusion Criteria:
• • 1. Previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation;
• • 2. Extrahepatic metastasis;
• • 3. History of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding;
• • 4. History of autoimmune disease or need to take immunosuppressant drugs for a long time;
• • 5. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
• • 6. Abnormal organ function